Ronald B. Goldberg

Ronald B. Goldberg

Auto-generated profile, based on publicly available information

Ronald B. Goldberg

University of Miami Miller School of Medicine, Miami, FL

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2008 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
RGRonald B. Goldberg
Ronald B. Goldberg
VFVivian A. Fonseca
Vivian A. Fonseca
KTKenneth E. Truitt
Kenneth E. Truitt
MJMichael R. Jones
Michael R. Jones
Type 2 diabetes mellitus (T2DM) is a well-known cardiovascular risk factor and a common cause of morbidity and mortality. It is well established that a direct relationship exists between the degree of glycemic control and risk of microvascular complications.1-3 The goal of antidiabetes therapy is to maintain plasma glucose levels as close to normal as possible. The American Diabetes Association recommends a glycated hemoglobin A1c (HbA1c) goal of less than 7.0% (to convert to a proportion of total hemoglobin, multiply by 0.01), the level at which clinical trials have demonstrated fewer long-term microvascular and macrovascular complications.4 However, data from the 1999-2000 National Health and Nutrition Examination Survey suggest that only 37% of patients with T2DM achieve this goal.5

23 May 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
RGRonald B. Goldberg
Ronald B. Goldberg
TOTrevor J. Orchard
Trevor J. Orchard
JCJill P. Crandall
Jill P. Crandall
EBEdward J. Boyko
Edward J. Boyko
Matthew Jay BudoffMatthew Jay Budoff
Matthew Jay Budoff
OGon behalf of the Diabetes Prevention Program Research Group*
on behalf of the Diabetes Prevention Program Research Group*
Background: Lifestyle intervention and metformin have been shown to prevent diabetes; however, their efficacy in preventing cardiovascular disease associated with the development of diabetes is unclear. We examined whether these interventions reduced the incidence of major cardiovascular events over a 21-year median follow-up of participants in the DPP trial (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcomes Study). Methods: During DPP, 3234 participants with impaired glucose tolerance were randomly assigned to metformin 850 mg twice daily, intensive lifestyle or placebo, and followed for 3 years. During the next 18-year average follow-up in DPPOS, all participants were offered a less intensive group lifestyle intervention, and unmasked metformin was continued in the metformin group. The primary outcome was the first occurrence of nonfatal myocardial infarction, stroke, or cardiovascular death adjudicated by standard criteria. An extended cardiovascular outcome included the primary outcome or hospitalization for heart failure or unstable angina, coronary or peripheral revascularization, coronary heart disease diagnosed by angiography, or silent myocardial infarction by ECG. ECGs and cardiovascular risk factors were measured annually. Results: Neither metformin nor lifestyle intervention reduced the primary outcome: metformin versus placebo hazard ratio 1.03 (95% CI, 0.78–1.37; P = 0.81) and lifestyle versus placebo hazard ratio 1.14 (95% CI, 0.87–1.50; P = 0.34). Risk factor adjustment did not change these results. No effect of either intervention was seen on the extended cardiovascular outcome. Conclusions: Neither metformin nor lifestyle reduced major cardiovascular events in DPPOS over 21 years despite long-term prevention of diabetes. Provision of group lifestyle intervention to all, extensive out-of-study use of statin and antihypertensive agents, and reduction in the use of study metformin together with out-of-study metformin use over time may have diluted the effects of the interventions. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: DPP (NCT00004992) and DPPOS (NCT00038727).

23 October 2020 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
RGRonald B. Goldberg
Ronald B. Goldberg
ACAlan Chait
Alan Chait
The chylomicronemia syndrome is characterized by severe hypertriglyceridemia and fasting chylomicronemia and predisposes affected individuals to acute pancreatitis. When due to very rare monogenic mutations in the genes encoding the enzyme, lipoprotein lipase, or its regulators, APOC2, APOA5, GPIHBP1, and LMF1, it is referred to as the familial chylomicronemia syndrome. Much more frequently, the chylomicronemia syndrome results from a cluster of minor genetic variants causing polygenic hypertriglyceridemia, which is exacerbated by conditions or medications which increase triglyceride levels beyond the saturation point of triglyceride removal systems. This situation is termed the multifactorial chylomicronemia syndrome. These aggravating factors include common conditions such as uncontrolled diabetes, overweight and obesity, alcohol excess, chronic kidney disease and pregnancy and several medications, including diuretics, non-selective beta blockers, estrogenic compounds, corticosteroids, protease inhibitors, immunosuppressives, antipsychotics, antidepressants, retinoids, L-asparaginase, and propofol. A third uncommon cause of the chylomicronemia syndrome is familial forms of partial lipodystrophy. Development of pancreatitis is the most feared complication of the chylomicronemia syndrome, but the risk of cardiovascular disease as well as non-alcoholic steatohepatitis is also increased. Treatment consists of dietary fat restriction and weight reduction combined with the use of triglyceride lowering medications such as fibrates, omega 3 fatty acids and niacin. Effective management of aggravating factors such as improving diabetes control, discontinuing alcohol and replacing or reducing the dose of medications that raise triglyceride levels is essential. Importantly, many if not most cases of the chylomicronemia syndrome can be prevented by effective identification of polygenic hypertriglyceridemia in people with conditions that increase its likelihood or before starting medications that may increase triglyceride levels. Several new pharmacotherapeutic agents are being tested that are likely to considerably improve treatment of hypertriglyceridemia in people at risk.

1 December 2006 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
RGRonald B. Goldberg
Ronald B. Goldberg
JGJohn R. Guyton
John R. Guyton
TMTheodore Mazzone
Theodore Mazzone
RWRuth S. Weinstock
Ruth S. Weinstock
APAdam Polis
Adam Polis
ATAndrew M. Tershakovec
Andrew M. Tershakovec

1 April 2008 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
RGRonald B. Goldberg
Ronald B. Goldberg
TJTerry A. Jacobson
Terry A. Jacobson

1 June 2017 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
CFCecilia Frej
Cecilia Frej
AMArmando J. Mendez
Armando J. Mendez
MRMario Ruiz
Mario Ruiz
MCMelanie Castillo
Melanie Castillo
THThomas A. Hughes
Thomas A. Hughes
RGRonald B. Goldberg
Ronald B. Goldberg
Objective—: Type 1 diabetes mellitus (T1D) patients have an increased risk of cardiovascular disease despite high levels of high-density lipoproteins (HDL). Apolipoprotein M (apoM) and its ligand sphingosine 1-phospate (S1P) exert many of the anti-inflammatory effects of HDL. We investigated whether apoM and S1P are altered in T1D and whether apoM and S1P are important for HDL functionality in T1D. Approach and Results—: ApoM and S1P were quantified in plasma from 42 healthy controls and 89 T1D patients. HDL was isolated from plasma and separated into dense, medium-dense, and light HDL by ultracentrifugation. Primary human aortic endothelial cells were challenged with tumor necrosis factor-α in the presence or absence of isolated HDL. Proinflammatory adhesion molecules E-selectin and vascular cellular adhesion molecule-1 were quantified by flow cytometry. Activation of the S1P 1 - receptor was evaluated by analyzing downstream signaling targets and receptor internalization. There were no differences in plasma levels of apoM and S1P between controls and T1D patients, but the apoM/S1P complexes were shifted from dense to light HDL particles in T1D. ApoM/S1P in light HDL particles from women were less efficient in inhibiting expression of vascular cellular adhesion molecule-1 than apoM/S1P in denser particles. The light HDL particles were unable to activate Akt, whereas all HDL subfractions were equally efficient in activating Erk and receptor internalization. Conclusions—: ApoM/S1P in light HDL particles were inefficient in inhibiting tumor necrosis factor-α–induced vascular cellular adhesion molecule-1 expression in contrast to apoM/S1P in denser HDL particles. T1D patients have a higher proportion of light particles and hence more dysfunctional HDL, which could contribute to the increased cardiovascular disease risk associated with T1D.